A Claudio Cuello, OC, MD, DSc, FRSC, FMedSci, FMedSci

Affiliations: 
1985- Pharmacology And Therapeutics McGill University, Montreal, QC, Canada 
Area:
Alzheimer's Disease, cognitive behavior, neurochemistry, immunocytochemistry, neuropharmacology and molecular biology.
Google:
"A Claudio Cuello"
Bio:

Since 2003, he has been the Charles E. Frosst/Merck endowed Chair in Pharmacology at McGill University. He leads a research team on multidisciplinary aspects (cognitive behavior, neurochemistry, immunocytochemistry, neuropharmacology and molecular biology) of brain aging and Alzheimer’s disease neuropathology. The Cuello Lab is comprised of talented and motivated colleagues focused on unravelling the earliest biochemical-pathological events of the Alzheimer’s pathology as well as searching for early biomarkers and novel experimental therapies to arrest or revert the early Alzheimer’s pathology. His group has recently made important contributions to the understanding of CNS trophic factor deregulation both in Alzheimer’s disease and in Down syndrome.

(Show more)

Mean distance: 13.39 (cluster 11)
 
SNBCP
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Hampel H, Vergallo A, Caraci F, et al. (2020) Future avenues for Alzheimer's disease detection and therapy: Liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery. Neuropharmacology. 108081
Hampel H, Caraci F, Cuello AC, et al. (2020) A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease. Frontiers in Immunology. 11: 456
Welikovitch LA, Do Carmo S, Maglóczky Z, et al. (2020) Early intraneuronal amyloid triggers neuron-derived inflammatory signaling in APP transgenic rats and human brain. Proceedings of the National Academy of Sciences of the United States of America
Wilson EN, Do Carmo S, Welikovitch LA, et al. (2019) NP03, a Microdose Lithium Formulation, Blunts Early Amyloid Post-Plaque Neuropathology in McGill-R-Thy1-APP Alzheimer-Like Transgenic Rats. Journal of Alzheimer's Disease : Jad
Hampel H, Vergallo A, Afshar M, et al. (2019) Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease
. Dialogues in Clinical Neuroscience. 21: 177-191
Martino Adami PV, Nichtová Z, Weaver DB, et al. (2019) Perturbed mitochondria-ER contacts in live neurons modelling Alzheimer's disease amyloid pathology. Journal of Cell Science
Pascoal TA, Mathotaarachchi S, Kang MS, et al. (2019) Aβ-induced vulnerability propagates via the brain's default mode network. Nature Communications. 10: 2353
Malcolm JC, Breuillaud L, Do Carmo S, et al. (2019) Neuropathological changes and cognitive deficits in rats transgenic for human mutant tau recapitulate human tauopathy. Neurobiology of Disease
Cuello AC, Hall H, Do Carmo S. (2019) Experimental Pharmacology in Transgenic Rodent Models of Alzheimer's Disease. Frontiers in Pharmacology. 10: 189
Cuello AC, Pentz R, Hall H. (2019) The Brain NGF Metabolic Pathway in Health and in Alzheimer's Pathology. Frontiers in Neuroscience. 13: 62
See more...